Academic Journals Database
Disseminating quality controlled scientific knowledge

Generics and Biosimilars Initiative Journal

ISSN: 2033--6403
Publisher: Pro Pharma Communications International


ADD TO MY LIST
 
Statin generics: no differences in efficacy after switching

Author(s): Christoph Baumgärtel, MD
Volume: 1
Issue: 3-4
Year: 2012
Pharmacovigilance of biosimilars: challenges and possible solutions

Author(s): Thijs J Giezen, PharmD, PhD | Sabine MJM Straus, MD, PhD
Volume: 1
Issue: 3-4
Year: 2012
The potential for doctors to contribute to biosimilar guidelines

Author(s): GaBI Journal Editor
Volume: 1
Issue: 3-4
Year: 2012
The MEDICRIME Convention: criminalising the falsification of medicines and similar crimes

Author(s): Susanne Keitel, MD
Volume: 1
Issue: 3-4
Year: 2012
Reference pricing systems in Europe: characteristics and consequences

Author(s): Pieter Dylst, PharmD | Professor Steven Simoens, MSc, PhD | Professor Arnold G Vulto, PharmD, PhD
Volume: 1
Issue: 3-4
Year: 2012
Terminology for biosimilars–a confusing minefield

Author(s): Robin Thorpe, PhD, FRCPath | Meenu Wadhwa, PhD
Volume: 1
Issue: 3-4
Year: 2012
Health professionals in the risk communication process on counterfeit medicines

Author(s): Luc Besançon
Volume: 1
Issue: 3-4
Year: 2012
Saving money in the European healthcare systems with biosimilars

Author(s): Robert Haustein | Christoph de Millas | Ariane Höer, MD | Professor Bertram Häussler, MD
Volume: 1
Issue: 3-4
Year: 2012
Austria could save Euros 256 million by using more generics

Author(s): Christoph Baumgärtel, MD
Volume: 1
Issue: 3-4
Year: 2012
A bioethicist’s view of the use of biosimilars

Author(s): Carlo Petrini, PhD
Volume: 1
Issue: 3-4
Year: 2012
A clinician’s view of the ethics of the use of biosimilars

Author(s): Dr Kalle Hoppu
Volume: 1
Issue: 3-4
Year: 2012
ICH Q11: development and manufacture of drug substances–chemical and biotechnological/biological entities

Author(s): Keith McDonald, MSc, MRPharmS | Kowid Ho, PhD
Volume: 1
Issue: 3-4
Year: 2012
Generics policies–a globally-relevant implementation challenge

Author(s): Andy Gray, MSc(Pharm), FPS
Volume: 1
Issue: 3-4
Year: 2012
Reference price systems: stakeholder dialogue and involvement

Author(s): Sabine Vogler, PhD
Volume: 1
Issue: 3-4
Year: 2012
Latest features in GaBI Journal, 2012, issue 3-4

Author(s): Professor Philip Walson, MD
Volume: 1
Issue: 3-4
Year: 2012
The potential of generics policies: more room for exploitation–PPRI Conference Report

Author(s): Sabine Vogler, PhD
Volume: 1
Issue: 3-4
Year: 2012
What lessons can be learned from the launch of generic clopidogrel?

Author(s): Christoph Baumgärtel, MD | Brian Godman, BSc, PhD | Rickard E Malmstrom, MD, PhD | Morten Andersen, MD, PhD | Mohammed Abuelkhair, PharmD | Shajahan Abdu, MD | Marion Bennie, MSc | Iain Bishop, BSc | Thomas Burkhardt, MSc | Sahar Fahmy, PhD | Jurij Furst | Kristina Garuoliene, MD, PhD | Harald Herholz, MPH | Marija Kalaba, MD, MHM | Hanna Koskinen, PhD | Ott Laius, MScPharm | Julie Lonsdale, BSc | Kamila Malinowska, MD | Anne M Ringerud, MScPharm | Ulrich Schwabe, MD, PhD | Catherine Sermet, MD | Peter Skiold, MSc, PhD | Ines Teixeira, BA, MSc | Menno van Woerkom, MSc | Agnes Vitry, PharmD, PhD | Luka Vončina, MD, MSc | Corrine Zara, PharmD | Professor Lars L Gustafsson, MD, PhD
Volume: 1
Issue: 2
Year: 2012
Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach

Author(s): Brian Godman, BSc, PhD | Mohammed Abuelkhair, PharmD | Agnes Vitry, PharmD, PhD | Shajahan Abdu, MD | Marion Bennie, MSc | Iain Bishop, BSc | Sahar Fahmy, PhD | Kristina Garuoliene, MD, PhD | Harald Herholz, MPH | Andrew Martin, BSc, MPharmS | Rickard E Malmstrom, MD, PhD | Professor Saira Jan, PharmD, PhD | Ulrich Schwabe, MD, PhD | Catherine Sermet, MD | Peter Skiold, MSc, PhD | Luka Voncina, MD, MSc | Professor Lars L Gustaffson, MD, PhD
Volume: 1
Issue: 2
Year: 2012
Tighter EU rules on pharmacovigilance for biologicals

Author(s): GaBI Journal Editor
Volume: 1
Issue: 2
Year: 2012
Readers' Comments

Author(s): GaBI Journal Editor
Volume: 1
Issue: 2
Year: 2012
Promoting access to biosimilars: a public−private partnership model for biosimilar development in underserved populations

Author(s): Timothy Ken Mackey, MAS | Professor Bryan A Liang, MD, JD, PhD
Volume: 1
Issue: 2
Year: 2012
Generic clopidogrel–the medicines agency’s perspective

Author(s): Christoph Baumgärtel, MD
Volume: 1
Issue: 2
Year: 2012
Generics substitution in primary care: summary of the Dutch community pharmacies guidelines

Author(s): Leonora Grandia, PharmD | Professor Arnold G Vulto, PharmD, PhD
Volume: 1
Issue: 2
Year: 2012
Equal protection under the law: Children and the Best Pharmaceuticals for Children Act

Author(s): Professor Daniel Kelly Benjamin Jr, MD, MPH, PhD | Professor Gregory L Kearns, PharmD, PhD
Volume: 1
Issue: 2
Year: 2012
What to look forward to in GaBI Journal, 2012, issue 2

Author(s): Professor Philip Walson, MD
Volume: 1
Issue: 2
Year: 2012
Abstracted Scientific Content

Author(s): GaBI Journal Editor
Volume: 1
Issue: 2
Year: 2012
Biosimilars in the European market

Author(s): Professor Joan Rovira, PhD | Leandro Lindner, BSc | Emmanuel Giménez, BSc | Professor Jaime Espín, PhD | Antonio Olry de Labry, PhD | Leticia García, BSc
Volume: 2
Issue: 1
Year: 2013
Current status of biopharmaceuticals in Iran’s pharmaceutical market

Author(s): Professor Abdol Majid Cheraghali, PharmD, PhD
Volume: 2
Issue: 1
Year: 2013
Assessing biosimilarity and interchangeability of biosimilar products under the Biologics Price Competition and Innovation Act

Author(s): Professor Shein-Chung Chow, PhD | Christine Ju, MSc
Volume: 2
Issue: 1
Year: 2013
PMDA update: the current situation and future directions

Author(s): Yuki Ando, BA | Toshiyoshi Tominaga, PhD | Tatsuya Kondo, MD, PhD
Volume: 2
Issue: 1
Year: 2013
‘Similar biologics’ approved and marketed in India

Author(s): GaBI Journal Editor
Volume: 2
Issue: 1
Year: 2013
The future of biological therapy: a pathway forward for biosimilars

Author(s): Richard O Dolinar, MD | Michael S Reilly
Volume: 2
Issue: 1
Year: 2013
The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation

Author(s): Fereshteh Barei, PhD | Professor Claude Le Pen | Professor Steven Simoens, MSc, PhD
Volume: 2
Issue: 1
Year: 2013
Austria increases dialogue in order to involve physicians more with biosimilars

Author(s): Christoph Baumgärtel, MD
Volume: 2
Issue: 1
Year: 2013
The ethics of biosimilars

Author(s): Christian K Schneider, MD
Volume: 2
Issue: 1
Year: 2013
New CHMP Guideline on immunogenicity of monoclonal antibodies

Author(s): Robin Thorpe, PhD, FRCPath | Meenu Wadhwa, PhD
Volume: 2
Issue: 1
Year: 2013
IAPO launched the Patient-Centred Healthcare Indicators Review

Author(s): Yasemin Dil
Volume: 2
Issue: 1
Year: 2013
Health authority perspective on biosimilars

Author(s): Brian Godman, BSc, PhD
Volume: 2
Issue: 1
Year: 2013
The case for biosimilars–a payer’s perspective

Author(s): Gustaf Befrits
Volume: 2
Issue: 1
Year: 2013
Alleviating concerns around generic antiepileptic medications

Author(s): GaBI Journal Editor
Volume: 2
Issue: 1
Year: 2013
Rythym

Author(s): GaBI Journal Editor
Volume: 1
Issue: 1
Year: 2012
A review of generic medicine pricing in Europe

Author(s): Professor Steven Simoens, MSc, PhD
Volume: 1
Issue: 1
Year: 2012
Biologicals and biosimilars: a review of the science and its implications

Author(s): Professor Paul J Declerck, PhD
Volume: 1
Issue: 1
Year: 2012
A patient-centred paradigm for the biosimilars market

Author(s): James N Class, PhD | Lauren Langis, JD
Volume: 1
Issue: 1
Year: 2012
European payer initiatives to reduce prescribing costs through use of generics

Author(s): Brian Godman, BSc, PhD | Bjorn Wettermark, MSc, PhD | Iain Bishop, BSc | Thomas Burkhardt, MSc | Jurij Fürst, PhD | Kristina Garuoliene, MD | Ott Laius, MScPharm | Jaana E Martikainen, Lic Sc(Pharm) | Catherine Sermet, MD | Inês Teixeira, BA, MSc | Corrine Zara, PharmD | Lars L Gustafsson, MD, PhD
Volume: 1
Issue: 1
Year: 2012
A review of patient perspectives on generics substitution: what are the challenges for optimal drug use

Author(s): Helle Håkonsen, MScPharm, PhD | Else-Lydia Toverud, MScPharm, PhD
Volume: 1
Issue: 1
Year: 2012
Myths, questions, facts about generic drugs in the EU

Author(s): Christoph Baumgärtel, MD
Volume: 1
Issue: 1
Year: 2012
Generic and therapeutic orphans

Author(s): Professor Philip Walson, MD
Volume: 1
Issue: 1
Year: 2012
Generic medicine pricing: on track in Europe?

Author(s): Associate Professor Marc A Koopmanschap, PhD
Volume: 1
Issue: 1
Year: 2012
Introduction to the GaBI Journal

Author(s): Professor Philip Walson, MD
Volume: 1
Issue: 1
Year: 2012
Innovator companies should focus on innovations

Author(s): Professor Theodor Dingermann, PhD
Volume: 1
Issue: 1
Year: 2012
How matrix models can support generic medicine prescribing

Author(s): Robert Janknegt, PharmD, PhD
Volume: 1
Issue: 1
Year: 2012
Why do you need a reservation system?      Affiliate Program